dataesr/scientific-paragraphs-categorization huggingface dataset:
RADIANCE-HTN and REQUIRE clinical study designs The RADIANCE-HTN (ClinicalTrials. gov identifier NCT02649426) and REQUIRE (ClinicalTrials. gov identifier NCT02918305) clinical studies are designed to assess the BP-lowering efficacy of the Paradise Renal Denervation System in adult patients with hypertension in the United States, Europe, Japan, and Korea. These studies are funded by Otsuka Holdings Co, Ltd, and ReCor Medical, Inc. Leslie Coleman, DVM, MS, DACLAM, an employee of ReCor Medical, helped with the writing, editing, and formatting of this article.
SOLO cohort TRIO cohort Step 1 (2 mo after randomization) Add mid-dose long-acting dihidropyridine calcium-channel blocker (preferentially amlodipine 5 mg) Add spironolactone (25-50 mg) Step All randomized subjects will undergo a safety-driven renal duplex ultrasound at 2 and 6 months. In addition, subjects randomized to renal denervation will undergo a safety-driven renal CT angiogram at 12 months to assess renal artery anatomy, with continued monitoring of renal artery anatomy by duplex ultrasound at 24 and 36 months. All subjects will be followed up for 3 years; all safety data will be collected for 3 years (see Appendix C for safety assessments).
BP measurements Office BP monitoring will be conducted using a validated automated device (Omron HEM-907), monthly for the first 6 months after procedure and at 12 months. Blood pressure measurement techniques will be standardized. All measurements will be obtained in the seated position using the same arm throughout the study. Ambulatory BP monitoring will be performed using a validated portable automated device (TM-243 series; A&D, Corp, Tokyo, Japan) before the procedure and at 3, 6, and 12 months after procedure. Blood pressure will be measured every 30 minutes throughout the day. All subjects will remain blinded through 6 months. All subjects will be followed up for 12 months; all safety data will be collected for 12 months (see Appendix D for safety assessments).
Dr Daemen  reports research grants from  ReCor Medical ,  St Jude ,  Medtronic ,  Boston Scientific ,  Acist , and  Biotronik. Dr Davies  has received consultancy payments and research support from  Medtronic  and  ReCor. Dr Kirtane  reports institutional research grants to  Columbia University  and the  Cardiovascular Research Foundation from Boston Scientific ,  Medtronic ,  ReCor Medical , and  Abott Vascular. Dr Mahfoud  is supported by  Deutsche Hochdruckliga and Deutsche Gesellschaft für Kardiologie  and has received speaker honoraria and consultancy fees from  Medtronic  and  ReCor. Dr Schemieder  has received speaker fees, consultancy and advisory board fees, and other from  Kona Medical ,  Medtronic , and Recor. The  University Hospital  has received research funding from  Ablative Solutions, Medtronic, Roxmedical, KONA , and  ReCor.
The results are compared with literature data and chemodynamical models. Methods. We studied the spectra obtained for a large sample of red giant stars, chosen to be one magnitude above the horizontal branch, using FLAMES-GIRAFFE on the Very Large Telescope. We computed the O abundances using the forbidden [OI] 6300. 3 Å and Zn abundances using the Zn I 6362. 34 Å lines. Stellar parameters for these stars were established in a previous work from our group. Results. We present oxygen abundances for 358 stars, nitrogen abundances for 403 stars and zinc abundances were derived for 333 stars. Having oxygen abundances for this large sample adds information in particular at the moderate metallicities of -1. 6<[Fe/H]<-0. 8. Zn behaves as an α-element, very similarly to O, Si, and Ca. It shows the same trend as a function of metallicity as the α-elements, i.
Observations The present data were obtained using the FLAMES-GIRAFFE instrument at the 8. 2 m Kueyen of the Very Large Telescope, at the European Southern Observatory (ESO), in Paranal, Chile, as described in  Zoccali et al. (2008)  (ESO Projects 071. B-067, 071. B-0014; PI: A. Renzini). Targets are bulge K giants, with magnitudes ∼1. 0 above the red clump, originally in four fields. In the present work, we have analysed stars from two fields, reported in Table  2 , among the four fields studied in  Zoccali et al. (2008). These two fields were observed in setups HR13 (612. 0 -640. 5nm), ) and HR15 (660. 7 -696. 5nm), with resolving power respectively of R = 26,400, 18,000, and 21,350. The other two fields, NGC 6553 field at (l,b) = (5. • 25,3. • 02) and Blanco field at (l,b) = (0 • ,12 • ), observed with setups HR11, HR13, and HR15, were reanalysed by  Johnson et al.
In Table  3  we report the stellar parameters and N, O, and Zn abundances for the 23 stars from both UVES and GIRAFFE data. In Fig. 1  we compare the abundances of O, N, and Zn derived from the GIRAFFE data with those derived from the UVES spectra. The oxygen abundances are in very good agreement. Nitrogen abundances appear somewhat higher in GIRAFFE spectra with respect to those in UVES. For N we could not refit C, since we have no atomic or molecular line for this element, and this may be the source of the discrepancy. Zinc tends to be lower in GIRAFFE spectra than in the UVES ones; in Fig. 1  the difference is larger for the UVES values given for the mean of abundances derived from the two lines Zn I 4810. 5 and 6362. 3 Å, and less discrepant when comparing results for the same line as in the GIRAFFE spectra.
2, 0. 4, ∆v t = +0. 1, 0. 2, 0. 3 km s -1 , for UVES and GIRAFFE data respectively, and corresponding total error, applied to the stellar parameters T eff , log g, [Fe/H], v t of stars BW-b6 (4200 K, 1. 7, -0. 25, 1. 3 km. s -1 ), and B6-b3 (4700 K, 2. 0, 0. 10, 1. 6 km. s -1 ). The errors are given such as the difference is the amount needed to recover the correct fit.
6<[Fe/H]<-0. 9. There is therefore a mismatch between the models and the data in this metallicity range. It is important to note that chemodynamical models are suitable to indicate the inflexion of the [X/Fe] values due to enrichment of Fe from SNIa. At the high metallicity end, since there is progressive enrichment in Fe by SNIa, a constant [Zn/Fe] would imply that there is chemical enrichment in both Zn and Fe on similar timescales. Instead, a decrease of [Zn/Fe] would correspond to the enrichment in Fe by SNIa, with no enrichment in Zn by the same SNIa, as happens for the α-elements. This discrepancy has been addressed by  Duffau et al. (2017) , who found, at supersolar metallicities, a decreasing [Zn/Fe] for red giants, and constant [Zn/Fe] for dwarfs. Their interpretation is that the dwarfs are old and the red giants are young.
Acknowledgements. CRS acknowledges a  CAPES/PROEX  PhD fellowship. BB and AF acknowledge partial financial support by  CNPq ,  CAPES  and  FAPESP. MZ and DM acknowledge support by the  Ministry of Economy, Development, and Tourism's Millenium Science Initiative  through grant  IC120009 , awarded to The  Millenium Institute of Astrophysics, MAS , and from the  BASAL Center for Astrophysics and Associated Technologies   PFB-06  and  FONDECYT Projects 1130196  and  1150345. SO acknowledges the  Italian Ministero dell'Università e della Ricerca Scientifica e Tecnologica (MURST), Italy.
Optimizing Currently Approved Doses of Dasatinib The currently approved doses of dasatinib resulted from 2 long-term pivotal trials aimed at maximizing efficacy while minimizing AEs. The CA180-034 trial enrolled patients with imatinib-resistant or imatinib-intolerant CML-CP. 9 This study compared dasatinib at a dose of 100 or 140 mg per day, and once-daily or twice-daily schedules, to determine the optimal dosage and regimen. The results indicated that dasatinib treatment at a dose of 100 mg once daily demonstrated durable efficacy and a tolerable long-term safety profile. The data obtained from this study should be considered the proof of principle that the daily dose of dasatinib can be lowered, from 70 mg twice per day (a total dose of 140 mg per day) to 100 mg once per day in particular, while maintaining efficacy in patients intolerant of or resistant to imatinib.
Efficacy and safety There are published data indicating that modifying the dasatinib dose from 100 mg once daily can mitigate significant AEs yet maintain efficacy over the long term. In the phase 2 DARIA-01 study, patients with CML-CP were enrolled to determine factors influencing adherence and efficacy when AEs from dasatinib were managed with dose modifications. 11 Patients had their dasatinib doses reduced from 100 mg per day to 50 mg per day when they experienced a nonhematologic AE of grade 2 or a hematologic AE of grade 3. In this small study, approximately 25% of patients had their doses reduced in the first 3 months, and 34% had their doses reduced in the first 6 months. At 6 months, 25 patients (78%) achieved a complete cytogenetic response (CCyR) and 13 (40%) achieved a major molecular response (MMR).
Preliminary results of OPTIM DASATINIB demonstrated that patients allocated to this therapeutic drug monitoring strategy showed a reduced risk of pleural effusion without impairment of the kinetics of response. By 24 months, approximately 88% of the patients with high C min values who then had their dasatinib doses lowered achieved MMR; 69% achieved molecular response with a 4-log reduction of BCR-ABL1 transcripts (MR 4. 0 ); and 39% achieved MR  4. 5  , which is considered a complete molecular response/remission (CMR). Moreover, the dose optimization strategy reduced the risk of pleural effusion in the study population, which is consistent with the data obtained by Wang et al in their retrospective analysis described above. 13, 14 ntermittent dosing with dasatinib has been shown to improve tolerability in patients with CML who were resistant to or intolerant of imatinib.
Ongoing trials investigating dasatinib efficacy with dose optimization 9] [30] [31] [32] [33] [34] [35] [36]  Two of these studies, DARIA-01  11  and OPTIM DASATINIB,  14  have reported preliminary data and are described above. There are 4 studies currently under way to determine optimizing dasatinib doses in patients or patient subgroups. A low-dose study in Japan will evaluate the efficacy of 50 mg of dasatinib per day in patients who are resistant to or intolerant of low-dose imatinib; the primary outcome measure is MMR at 12 months. 28 The CML12 DIRECT (Dasatinib Intensity Regulation to Eliminate Cumulative Toxicities) study  29  will examine dose optimization of dasatinib in patients aged 60 years with CML. In this study, therapeutic daily monitoring will be used to optimize effective doses with minimal toxicity.
32 The Optimization of TKIs Treatment and Quality of Life trial will evaluate the efficacy of intermittent dasatinib dosing (1 month on/1 month off vs 1 month on/1 month off in year 1, 1 month on/2 months off in year 2, and 1 month on/3 months off in year 3) and the effect on QOL such dosing regimens may have; the primary outcome is changes in QOL at defined times. 33 inally, the DasPAQT (Treating Patients With Chronic Myeloid Leukemia in Chronic Phase With Dasatinib) trial is a real-life study to gather data regarding how CML is managed with dasatinib in practices outside of academic settings, including whether and when dose reductions are used. 34.
of Patients Enrolled) Single-arm (N 5 32) Two arms, randomized (N 5 289) Single-arm (N 5 30) b Single-arm (N 5 80) b Three arms, open-label (N 5 168) b Single-arm (N 5 100) b Two arms, randomized (N 5 306) b Trial Title A Phase 2 Study Of Midterm Compliance And Effectiveness Of Dasatinib Therapy In Patients With CML OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) Phase 2 Clinical Trial Of Low-Dose Dasatinib In Patients With Resistant Or Intolerant CML Who Are Treated With Low-Dose Imatinib The DIRECT study: Individualized Dasatinib Dosing For Elderly Patients With Chronic Myelogenous Leukemia De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia Therapy of Early Chronic Phase CML With Dasatinib Treatment optimization for patients with CML with treatment-na€ ıve disease (first-line) and patients with resistance or intolerance against alternative Abl-Kinase inhibitors (second-line) Registry Information UMIN000007345 (Japanese Ministry of Health; DARIA-01 study) 11,35 ClinicalTrials.
gov identifier NCT01916785 (OPTIM DASATINIB) 14,36 UMIN000003499 (Japanese Ministry of Health) 28 ACTRN12616000738426 (Australia; CML12 DIRECT) 29 ClinicalTrials. gov identifier NCT01804985 (DESTINY) 30 ClinicalTrials. gov identifier NCT02689440 31 LN_CMLSTU_2015_576 (European Leukemia Trial Registry; DasaHIT) 32.
of Patients Enrolled) Two arms, randomized (N 5 502) b Observational (N 5 300) b Trial Title Optimization of TKIs Treatment and Quality of Life in Ph1 CML Patients 60 Years in Deep Molecular Response Treating Patients With CML in Chronic Phase With Dasatinib Registry Information ClinicalTrials. gov identifier NCT02326311 33 ClinicalTrials. gov identifier NCT02348957 (DasPAQT) 34 Abbreviations: AE, adverse event; C min , minimal plasma concentration; CCyR, complete cytogenetic response; CML, chronic myeloid leukemia; CMR, complete molecular response; IS, International Scale; MMR, major molecular response (BCR-ABL1 [IS] < 0. 1%); NA, not available; OS, overall survival; PFS, progression-free survival; Ph1, Philadelphia chromosome positive; QOL, quality of life; TKI, tyrosine kinase inhibitor.
0 for 1 y CML-CP ECOG PS 0-1 Dasatinib 2 y MR 4. 5 1 y Treatment with second- generation TKI (dasatinib or nilotinib) 3 y MR 4. 5 2 y Newly diagnosed CML-CP ECOG PS 0-2 Adequate organ function CMR CML-CP ECOG PS 0-2 Adequate organ function CMR for 2 y CML-CP TKI treatment 3 y MMR for 1 y CML-CP Dasatinib for 2 y Arm(s) (No. of Patients Enrolled) 2 arms, randomized (N 5 289) Single-arm (N 5 88) Single-arm, open-label (N 5 71) Single-arm (N 5 100) Single-arm (N 5 100) b Single-arm, open-label (N 5 50) b Three arms, open-label (N 5 168) b Observational (N 5 133) b Trial Title OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) Dasatinib Discontinuation trial Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase CML With Stable Complete Molecular Response STOP second-generation (2G)-tyrosine kinase inhibitor (TKI) study Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia Front-line Treatment of BCR-ABL1 Chronic Myeloid Leukemia (CML) With Dasatinib Registry Information ClinicalTrials.
gov identifier NCT01916785 (OPTIM DASATINIB) 36,38 UMIN000005130 (Japanese Ministry of Health; DADI) 39 ClinicalTrials. gov identifier NCT01850004 (DASFREE) 40,41 STOP-2G-TKI study 42 ClinicalTrials. gov identifier NCT01887561 (D-NewS) 43 ClinicalTrials. gov identifier NCT01627132 (D-STOP) 44 ClinicalTrials. gov identifier NCT01804985 (DESTINY) 30 ClinicalTrials. gov identifier NCT01761890 (CML1113) 45.
0 2 y TKI ClinicalTrials. gov Treatment-free Remission Single-arm, open-label CML-CP Patients will take their own supply Molecular remission (change from identifier Accomplished With (N 5 135) b Imatinib treatment 3 y of imatinib for 3 mo to ensure baseline in molecular profile at NCT02268370 Dasatinib in Patients ECOG PS 2 stable responses, then imatinib 12 mo) (TRAD) 47 With CML Adequate organ liver and will be stopped and patients renal functions monitored for disease recur- MR 4. 5 rence; if patient has a recur- rence, then he or she will receive dasatinib for up to 2 y; if response is achieved after 1 y and maintained for another y, patient has the option to discontinue drug, with continued monitoring ClinicalTrials. gov European Stop Tyrosine Single-arm, open-label CML-CP Main goal is assessment of dura-Molecular recurrence-free survival identifier Kinase Inhibitor Study (N 5 800) b First-line or second-line TKI tion of MMR after stopping TKI NCT01596114 for 3 y therapy (EURO-SKI) 48 MR 4.
MeerLICHT and the need for some night time observations All of the ThunderKAT science benefits from having simultaneous optical data during the MeerKAT observations. For transients discovered in commensal searches, the simultaneous optical flux and radio flux density measurements of an astrophysical transient allow an initial classification (Stewart et al. 2016, in prep) which will assist in allocating and prioritising multi-wavelength follow-up resources. In this regard, ThunderKAT is already part of a consolidated multi-year South African-led program for rapid follow up of various classes of transients on the Southern African Large Telescope (SALT).
Acknowledgements This proceeding is an adapted version of the 2016 updated  ThunderKAT  project plan submitted to SKA South Africa in June 2016, ahead of the first light images of MeerKAT-16 released on 30 June 2016. The authorship of this manuscript reflects the full ThunderKAT membership at the time of submission of these proceedings, and are presented in the following order: the two principal investigators of ThunderKAT (Fender and Woudt), and alphabetical list of the work group leaders, followed by a second alphabetical list of ThunderKAT co-investigators. RF acknowleges partial support from the  European Research Council. PAW acknowledges the  University of Cape Town  and the  South African National Research Foundation  for financial support.
In return, real-estate developers receive property tax freezes for up to 10 years for new construction or 14 years for rehabilitation of existing sites (Chattanooga City Council 2016). Chattanooga Neighborhood Enterprise (CNE), a not-for-profit organization that is partially funded by the City of Chattanooga and foundations, has built affordable housing in downtown Chattanooga, such as the Grand Hotel. The organization also provides financial assistances, such as loans and mortgages, as well as assistance in case of foreclosure.
Design and study population We conducted a nested survival study using Druti study data  [4]. Druti was a national crosssectional prospective survey conducted in France between January 2012 and February 2013 by GPs of a French practice-based surveillance network, the "Sentinelles" network  [22]. The aim of Druti was to describe the patterns of antibiotic resistance of Enterobacteriaceae involved in community-acquired UTIs. Patients included were female aged 18 and older visiting their GP for suspected UTI (i. e. complaining of at least one clinical symptom of UTI-dysuria, urinary frequency or urinary urgency) for less than seven days. They had to agree to participate, to avoid any antibiotic during the seven previous days, and to be able to provide a midstream urine sample during the consultation.
Population of the Druti study is described elsewhere  [4]. For our nested study, a first population was formed, excluding patients with substantial arguments for pyelonephritis (temperature above 38. 5˚C) [23]  or who had not been followed-researchers, so as not to allow anonymity to be lifted. If the database is requested, the authors (that belong to the Sentinelles network) or another member of the Sentinelles network will rework the database as follows: date of birth will be replaced by the age under or over 55 at the time of the consultation. To access the data, researchers can send requests directly to the authors or to the Sentinelles network (dr. francois. m@gmail. com or sentinelles@upmc. fr). up to two weeks. From this population, a subgroup, also excluding patients with pelvic or back pain, was formed to rule out any patient who may have pyelonephritis.
Data collection For each included patient, GP and patient filled in a questionnaire during the consultation. It included questions regarding the description of the current episode, the bet of the patient and the GP on diagnosis of UTI, the therapeutic management, clinical status (risk factors of complications, previous UTIs. ) and patient's demographic characteristics. For the purposes of the Druti study, a urine sample was collected from all participants, and urine culture performed on all samples at the same laboratory (Ambroise PareUniversity Hospital, Paris). The GPs and the patients were blinded to the urine culture results. To recover any missing data, a trained investigator phoned GPs and patients to verify the information, within two weeks of inclusion. A questionnaire was given to the patient at baseline to note the daily evolution of symptoms over the next two weeks.
Ethical approval Before the inclusion, each patient completed a consent form. The data collected were anonymous. Each patient included received a 6-digit anonymity number: the first 4 digits corresponding to the doctor's identifier the last 2 digits corresponding to the patient number (01 for the first patient included). Thus, the third patient included by the doctor number 3760 was anonymized with the number 3760-03. The study obtained research authorization from the French independent administrative authority protecting privacy and personal data (CNIL), number 911,485 (CCTIRS number 11. 474), and from the local human investigation committee of Ile de France V.
Another symptoms like flank or abdominal pain, nausea or vomiting might occur during a pyelonephritis but the presence of these symptoms were not available in the database, preventing the distinction of pyelonephritis from cystitis in this way. Therefore in our study, the definition of pyelonephritis is limited to the presence of a temperature above 38. 5˚C. The presence of vaginal discharge or irritation decreases the likelihood of UTI in some studies  [6, 7]. However, a more recent meta-analysis concluded that vaginal discharge was a weak predictor of absence of infection  [48]. This is why we preferred not to exclude these patients. This study has several strengths. To our knowledge, this study is one of the first to systematically collect urine samples with centralized analysis from all women presenting with symptoms of a UTI in general practice.
Background: Pulmonary hemosiderosis is a rare and complex disease in children. A previous study from the French RespiRare® network led to two important findings: 20% of the children presented with both pulmonary hemosiderosis and Down syndrome (DS), and at least one tested autoantibody was found positive in 50%. This study investigates the relationships between pulmonary hemosiderosis and DS. Methods: Patients younger than 20 years old and followed for pulmonary hemosiderosis were retrieved from the RespiRare® database. Clinical, biological, functional, and radiological findings were collected, and DS and non-DS patients' data were compared. Results: A total of 34 patients (22 girls and 12 boys) were included, among whom nine (26%) presented with DS. The mean age at diagnosis was 4. 1 ± 3.
Patients Prevalent patients with pulmonary hemosiderosis were retrieved from the national RespiRare® database with a query on the words pulmonary hemosiderosis, alveolar hemorrhage, siderophage, Golde score and hemoptysis. The database and data collection have been approved by French national data protection authorities (CNIL n°9 08,324 and CCTIRS n°08. 015bis). Each patient and/or his or her legal representatives were informed prior to entering their data in the database. The charts of all the patients meeting the keywords were reviewed. Patients with a proven pulmonary hemosiderosis on BAL and/or lung biopsy between 1997 and 2017 were selected. Patients older than 20 years old at the time of the study were excluded.